223

Cetuximab (EGFR) Antibody, Monoclonal | 10-172

(No reviews yet) Write a Review
SKU:
223-10-172-GEN
€2,199.00

Description

Cetuximab (EGFR) Antibody, Monoclonal | 10-172 | Gentaur UK, US & Europe Distribution

Host: N/A

Reactivity: N/A

Homology: N/A

Immunogen: Chimeric / EGFR [Homo sapiens]

Research Area: Drug Analogues

Tested Application: N/A

Application: N/A

Specificiy: N/A

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: >95%

Clonality: Monoclonal

Clone: N/A

Isotype: IgG1-kappa

Conjugate: Unconjugated

Physical State: N/A

Buffer: PBS buffer pH7.5

Concentration: N/A

Storage Condition: Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 ˚C for 1-2 weeks. Store at -20 ˚C for 12 months. Store at -80 ˚C for long term storage.

Alternate Name: Fab C225, IMC-225

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: Cetuximab is an epidermal growth factor receptor binding FAB.Cetuximab is composed of the Fv (variable; antigen-binding) regions of the 225 murine EGFr monoclonal antibody specific for the N-terminal portion of human EGFr with human IgG1 heavy and kappa light chain constant (framework) regions.Cetuximab is marketed under the brand Erbitux® by Eli Lilly and Company.In the United States, a regimen of cetuximab costs approximately $30, 790 for an eight-week course.Cetuximab binds to the epidermal growth factor receptor (EGFr) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers.Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and TGF alpha, thereby reducing their effects on cell growth and metastatic spread.

View AllClose

Additional Information

Size:
0.1 mg
View AllClose